Top 15 Antisense Oligonucleotides Market Companies Investing Drugs in United States, Japan & GCC Growth Expansions (2026-2033)

DataM Intelligence has published a new research report on "Antisense Oligonucleotides Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/antisense-oligonucleotides-market?kb

United States: Recent Industry Developments

✅ May 2026: Biogen and Ionis Pharmaceuticals reported positive Phase 2 CELIA trial results for diranersen (BIIB080), marking the first antisense oligonucleotide therapy to demonstrate reduced tau pathology and cognitive benefit in early Alzheimer's disease.

✅ April 2026: Ionis Pharmaceuticals presented new pivotal clinical data for zilganersen, strengthening its antisense oligonucleotide pipeline for the treatment of Alexander disease.

✅ March 2026: Ionis Pharmaceuticals announced that the FDA accepted the New Drug Application (NDA) for zilganersen with Priority Review, advancing a potential first-in-class antisense therapy for Alexander disease.

✅ January 2026: Sarepta Therapeutics continued advancing its precision genetic medicine portfolio by expanding development programs for RNA-targeted therapies supporting future neuromuscular disease treatments.

Unlock growth potential in the Antisense Oligonucleotides Market with the right insights, partners, and strategic opportunities today: https://www.datamintelligence.com/partner-identification-enquiry/antisense-oligonucleotides-market?kb

Key Players:

Ionis Pharmaceuticals, Inc. Sarepta Therapeutics, Alnylam Pharmaceuticals, Inc. Percheron Therapeutics, Isarna Therapeutics GmbH, Novartis AG, Jazz Pharmaceuticals, Akcea Pharma, Genzyme and Biogen

Key Development:

🔹 In June 2026, Servier entered a multi-target research collaboration with n-Lorem Foundation to advance antisense oligonucleotide (ASO) therapies for rare neurodevelopmental disorders, combining Servier's R&D capabilities with n-Lorem's precision ASO platform.

🔹 In June 2026, Biogen announced that the U.S. FDA granted Breakthrough Therapy Designation to salanersen, its investigational once-yearly antisense oligonucleotide therapy for spinal muscular atrophy (SMA).

🔹 In June 2026, BioSpring expanded its strategic partnership with Luxna Biotech to include GuNATM amidites, strengthening next-generation oligonucleotide manufacturing capabilities for advanced ASO therapeutics.

🔹 In June 2026, Oak Hill Bio closed a US$32.5 million Series A financing to advance rugonersen, its investigational antisense oligonucleotide therapy for Angelman syndrome, into a pivotal Phase 3 clinical trial.

Growth Forecast Projected:

The Global Antisense Oligonucleotides Market is anticipated to rise at a considerable rate during the forecast period, between 2026 and 2032. In 2025, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Antisense Oligonucleotides Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Latest M & A 2026:

• May 2026: Biogen completed its acquisition of Apellis Pharmaceuticals, strengthening its rare disease portfolio and complementing its antisense oligonucleotide pipeline through expanded nephrology capabilities.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=antisense-oligonucleotides-market?kb

Japan: Recent Industry Developments
✅ May 2026: Nippon Shinyaku provided a regulatory update on RGX-121, confirming progress following the FDA's removal of the clinical hold and continued advancement of commercialization plans in Asia, including Japan.

✅ April 2026: Nippon Shinyaku entered a research collaboration with xFOREST Therapeutics to develop RNA structure-targeted drug discovery technologies, supporting next-generation RNA therapeutics.

✅ March 2026: Nippon Shinyaku expanded its rare disease pharmaceutical portfolio through the launch and co-promotion of specialty therapies, reinforcing its presence in advanced genetic and orphan disease treatments.

✅ January 2026: Nippon Shinyaku announced continued regulatory progress for RGX-111 and RGX-121, supporting development of innovative therapies for rare genetic disorders in Japan.

Key Segments:

By Drug Type: Enzyme Replacement Therapy (ERT), Hematopoietic Stem Cell Transplant (HSCT), Bone Marrow Transplantation (BMT) , Others

By Indication: Adult, Pediatric

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Lays the foundation by defining the scope of the report, highlighting core market segments across regions, product types, and applications. It delivers a clear snapshot of current market size, growth potential, and how the industry is expected to evolve in both the near and long term.

Chapter 2: Spotlights the most impactful market insights, unveiling the transformative trends and forces shaping the future of the industry.

Chapter 3: Provides a deep dive into the competitive landscape of , covering revenue shares, strategic initiatives, and notable mergers & acquisitions that are reshaping the market.

Chapter 4: Presents detailed company profiles of leading players featuring financial performance, product portfolios, profit margins, and key milestones that set them apart in the industry.

Chapters 5 & 6: Break down revenue analysis at both regional and country levels, offering precise data on market size, growth drivers, and expansion opportunities across global markets.

Chapter 7: Analyzes the market by product type, spotlighting segment-specific opportunities and helping stakeholders identify untapped, high-growth areas.

Chapter 8 :Explores the market through application-based segmentation, assessing demand across industries and pinpointing downstream sectors with the strongest potential for growth.

Chapter 9: Maps the industry's supply chain in detail, tracing upstream and downstream activities to provide clarity on value creation across the ecosystem.

Chapter 10: Wraps up with a concise summary of the report's key insights distilling the most critical findings and strategic takeaways for decision-makers and stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/antisense-oligonucleotides-market?kb

FAQ

Q1: What is the current size of the Antisense Oligonucleotides Market?

A: The Antisense Oligonucleotides Market was valued at US$ 3,180.1 million in 2025 and is forecasted to reach US$ 5,286.96 million by 2033

Q2: How rapidly will the Market expand?

A: The Antisense Oligonucleotides market is projected to grow at a CAGR of 6.5% between 2026 and 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?kb

Contact Us:
Sai Kiran
Business Development Manager
6th Floor, M2 Tech Hub, Lalitha Nagar, Habsiguda,
Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.